# BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

> **NCT02062684** · PHASE2,PHASE3 · COMPLETED · sponsor: **Anthera Pharmaceuticals** · enrollment: 57 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** Blisibimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02062684
- **Lead sponsor:** Anthera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2017-03
- **Final completion:** 2017-06-30
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2017-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02062684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02062684, "BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02062684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*